Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure
To directly compare the safety (by laboratory evaluation) and efficacy (feminization and growth) of three commonly used estrogen preparations in adolescent patients with ovarian failure, either due to congenital causes (Turner syndrome) or medical therapies. We hypothesize that transdermal estrogen will have equivalent efficacy and a more favorable safety profile in comparison with conventional oral estrogen replacement.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: 17beta Estradiol
- drug: Conjugated estrogens
- drug: 17Beta Estradiol - transdermal
- drug: Progesterone, micronized
Eligibility
Inclusion Criteria: in whom initiation of estrogen therapy has been recommended due to
ovarian failure
- Outpatients
- age >=12 years to 17.99 years old
Exclusion Criteria:
- spontaneous menses
- significant concurrent medical problem including:
- Liver function tests (LFTs) 3 times normal
- clotting disorder
- ongoing cancer treatment
Ages Eligible for Study
12 Years - 18 Years
Genders Eligible for Study
Female
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Sejal Shah
6507235791
Not Recruiting
Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation, mobile application development, and pharmaceutical trials.
Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.